Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Insights into Facilitated Subcutaneous Immunoglobulin Use in Patients with Secondary Immunodeficiency Diseases: A FIGARO Subgroup Analysis

Title: Insights into Facilitated Subcutaneous Immunoglobulin Use in Patients with Secondary Immunodeficiency Diseases: A FIGARO Subgroup Analysis
Authors: Maria Dimou; Matthaios Speletas; Cinzia Milito; Aleksandra Pyzik; Dörte Huscher; Marta Kamieniak; David Pittrow; Michael Borte
Source: Cancers, Vol 15, Iss 4524, p 4524 (2023)
Publisher Information: MDPI AG
Publication Year: 2023
Collection: Directory of Open Access Journals: DOAJ Articles
Subject Terms: facilitated subcutaneous immunoglobulin; immunoglobulin replacement therapy; secondary immunodeficiency diseases; real-world study; self-administration; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; RC254-282
Description: The Facilitated Immunoglobulin Administration Registry And Outcomes (FIGARO) Study was a European, multicenter, prospective, observational study conducted across Europe designed to provide insights on the clinical use and tolerability of facilitated subcutaneous immunoglobulin (fSCIG). Data herein are reported for the cohort of patients with secondary immunodeficiency (SID), with a subgroup analysis by age. The SID cohort included 31 patients: 1 pediatric, 15 adult, and 15 older adult patients. Over the 36-month observation period, the median monthly dose of fSCIG (30 g) and median monthly infusion volume per patient (300 mL) remained constant in both adult-age cohorts. Serum trough levels tended to increase over time. Most patients required only one infusion site and could receive the full dose every 3–4 weeks. There was a trend toward self-administration at home. In the adult group, infusion site inflammation and headache were reported at the inclusion visit ( n = 1 each), with no adverse drug reactions reported at any of the follow-up visits. No acute severe bacterial infections were reported during the study follow-up. These results demonstrate the feasibility and tolerability of fSCIG use in patients with SID and the flexibility of administration settings including self-administration at home in patients aged ≥65 years.
Document Type: article in journal/newspaper
Language: English
Relation: https://www.mdpi.com/2072-6694/15/18/4524; https://doaj.org/toc/2072-6694; https://doaj.org/article/17a4338f2dcc4af58eca4c8b4473361d
DOI: 10.3390/cancers15184524
Availability: https://doi.org/10.3390/cancers15184524; https://doaj.org/article/17a4338f2dcc4af58eca4c8b4473361d
Accession Number: edsbas.DF96E1F9
Database: BASE